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Cost of management of severe pneumonia in 
young children: systematic analysis 
Background Childhood pneumonia is a major cause 
of childhood illness and the second leading cause of 
child death globally. Understanding the costs associ-
ated with the management of childhood pneumonia 
is essential for resource allocation and priority setting 
for child health.
Methods We conducted a systematic review to iden-
tify studies reporting data on the cost of management 
of pneumonia in children younger than 5 years old. 
We collected unpublished cost data on non–severe, 
severe and very severe pneumonia through collabora-
tion with an international working group. We extract-
ed data on cost per episode, duration of hospital stay 
and unit cost of interventions for the management of 
pneumonia. The mean (95% confidence interval, CI) 
and median (interquartile range, IQR) treatment costs 
were estimated and reported where appropriate.
Results We identified 24 published studies eligible for 
inclusion and supplemented these with data from 10 
unpublished studies. The 34 studies included in the 
cost analysis contained data on more than 95 000 chil-
dren with pneumonia from both low– and–middle in-
come countries (LMIC) and high–income countries 
(HIC) covering all 6 WHO regions. The total cost (per 
episode) for management of severe pneumonia was 
US$ 4.3 (95% CI 1.5–8.7), US$ 51.7 (95% CI 17.4–
91.0) and US$ 242.7 (95% CI 153.6–341.4)–559.4 
(95% CI 268.9–886.3) in community, out–patient fa-
cilities and different levels of hospital in–patient set-
tings in LMIC. Direct medical cost for severe pneumo-
nia in hospital inpatient settings was estimated to be 
26.6%–115.8% of patients’ monthly household in-
come in LMIC. The mean direct non–medical cost and 
indirect cost for severe pneumonia management ac-
counted for 0.5–31% of weekly household income. 
The mean length of stay (LOS) in hospital for children 
with severe pneumonia was 5.8 (IQR 5.3–6.4) and 7.7 
(IQR 5.5–9.9) days in LMIC and HIC respectively for 
these children.
Conclusion This is the most comprehensive review to 
date of cost data from studies on the management of 
childhood pneumonia and these data should be help-
ful for health services planning and priority setting by 
national programmes and international agencies.
Electronic supplementary material:  
The online version of this article contains supplementary material.
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Pneumonia is one of the leading causes of morbidity and 
mortality in children under–five globally, and accounted for 
about 935 000 (15%) deaths in 2013 and 120 million new 
episodes of illness in this age group in 2010 [1,2]. Appro-
priate management of childhood pneumonia can reduce 
pneumonia–specific mortality by 32–72% [3–5] and thus 
accelerate the progress toward achievement of the Millen-
nium Development Goal 4 (MDG4). Childhood pneumonia 
places a large economic burden on families and the health 
care system, especially in resource–constrained low– and 
middle–income countries (LMIC). Severe ALRI is a substan-
tial burden on health services worldwide and a major cause 
of hospital referral and admission in young children [6]. Al-
though several studies in high–income as well as low– and 
middle–income countries have reported the costs associ-
ated with an episode of pneumonia (at the individual pa-
tient level), there are no published systematic reviews sum-
marizing the evidence from different health systems and 
settings globally. Bahia et al reviewed pneumococcal disease 
costs and productivity loss in Latin America and the Carib-
bean showed variation in unit costs of pneumococcal pneu-
monia at outpatient and inpatient levels [7]. We aimed to 
conduct a systematic review of published data on the costs 
associated with management of pneumonia episodes in chil-
dren younger than 5 years and to identify unpublished data 
sets from pneumonia research groups globally. Cost esti-
mates based on these data should be useful to develop mod-
els for estimating cost of management of pneumonia in 
community as well as hospital–based settings.
METHODS
Review of published studies
We aimed to identify all published studies reporting em-
pirical cost data on the treatment of episodes of pneumonia 
in children aged below 5 years during a 15–year period 
(1998–2013). We included studies in children younger 
than 5 years with pneumonia managed as in–patients or 
out–patients (using standard treatment per local standard) 
in secondary and tertiary hospitals, first level facility or in 
community settings. Data on the cost of a single episode of 
severe pneumonia from the societal and health care per-
spectives were collected as the primary study outcome. We 
developed a review protocol at the beginning of this study 
and followed the same throughout the process.
We undertook a systematic literature review with three re-
viewers (PS, IK, SZ), and hand searched reference list of all 
included articles. We searched four databases (with online 
search tools) to offer maximum coverage of the relevant lit-
erature: Medline, EMBASE, The Centre for Review and Dis-
semination Library (incorporating the DARE, NHS EED, 
and NHS HTA databases); and The Cochrane Library (via 
the Wiley Online Library) for the period 1 January 1998 to 
October 31 2013. (for search strategy, see Appendix S1 in 
Online Supplementary Document).
Three review authors (SZ, PS, IK) independently selected 
potentially relevant studies based on their title and abstract. 
Any disagreements in study selection or data extraction 
were resolved after discussion with SZ and HC. The eligible 
studies were retrieved electronically for full–text review. We 
included studies that investigated all–cause pneumonia in 
a non–selective population sample, reported empirical cost 
data for pneumonia treatment (using any intervention in-
cluding, but not limited to, antibiotics), and included only 
children younger than 5 years or reported data separately 
for this age group. We excluded review articles, vaccine 
cost–effectiveness trials, and studies considering specially 
selected cohorts with severe co–morbidity (Appendix S2 
in Online Supplementary Document). We developed and 
piloted a comprehensive data extraction template. We col-
lected data on cost per episode, cost and unit cost of med-
ication and services, duration of hospital stay and direct 
medical and non–medical costs. Direct medical cost in-
cluded costs related to medication, diagnostic tests, medi-
cal staff time and hospital stay. Direct non–medical costs 
included those relating to food, transportation and accom-
modation charges. Any additional data on indirect costs 
such as care–givers’ time and earning loss were also record-
ed, where available. Additionally, we extracted data on 
study characteristics including country, treatment setting, 
study type and sample size. We recorded the cost study 
perspective only if explicitly stated in the text of the article 
to avoid subjective influence. For those papers that did not 
explicitly state the perspective used, we noted “–“ for “un-
stated”.
We classified countries into high income and low–and–
middle income categories based on the classification ad-
opted by the World Bank and according to 2012 Gross Na-
tional Income (GNI) per capita, calculated using the World 
Bank Atlas method. The groups are low–income per capi-
ta US$ 1035 or less; lower middle–income US$ 1036–US$ 
4085; upper middle income US$ 4086–US$ 12 615; and 
high income US $12 616 or more [8].
Quality assessment
We assessed the quality of the included studies using a 13 
point scale based on a modified Drummond checklist [9] 
for economic evaluation focusing on the methodological 
robustness and detail of reporting (Appendix S3 in Online 
Supplementary Document). Studies were considered 
high quality if more than 10 points were addressed, me-
dium quality studies covered 7–9 points and low quality 
studies addressed less than 6 points. Studies with all qual-
ity levels were included in the final analysis.
June 2016  •  Vol. 6 No. 1 •  010408	 2	 www.jogh.org •  doi: 10.7189/jogh.06.010408
V
IE
W
PO
IN
TS
PA
PE
RS
Cost of managing severe pneumonia in young children
Unpublished data collection
We collected unpublished data from 10 collaborating sites 
that were part of a Severe ALRI Working Group (SAWG) 
[6]. The study population included children under 5 years 
of age with a clinical diagnosis of pneumonia. We defined 
pneumonia using the World Health Organization’s (WHO) 
Integrated Mangement of Childhood Illness (ICMI) defini-
tion by three different severity categories: non–severe, se-
vere and very severe pneumonia based on WHO pocket 
book for hospital care for children 2005 [10]. We included 
all interventions for pneumonia management as detailed in 
the WHO pocket–book (for community/and facility–based 
management) where data were available.
We designed a costing spreadsheet with detailed descrip-
tions of case definitions and methods and used this for data 
collection. Actual cost of medications, supplies, personnel 
and average laboratory costs were collected. Methods used 
to gather primary cost data in these studies were recorded 
in the spreadsheet. Resource utilization data from patient 
records were also documented, where available, including 
length of stay in hospital, the quantity of drugs and sup-
plies utilized by each patient, and the use of diagnostic tests 
and procedures. We also attempted to collect data on out–
of–pocket spending (by patients) on transport and food 
where possible. Indirect cost of caregivers’ time and daily 
pay rate were also recorded. Primary data collection was 
conducted using the provided standardized templates and 
guidelines at individual study site. (Appendix S4 in Online 
Supplementary Document).
We used a bottom–up approach to calculate cost per epi-
sode for each level of the intervention (community, first 
level health facility and hospital). Costs were calculated and 
presented separately based on severity and service delivery 
channels: very severe pneumonia at hospital level (defined 
as pneumonia with central cyanosis, inability to breastfeed 
or drink, or vomiting everything, convulsions, lethargy or 
unconsciousness and severe respiratory distress diagnosed 
by doctor or physicians using WHO IMCI (2005) case def-
inition or pneumonia cases requires critical care); severe 
pneumonia at hospital level (defined as pneumonia with 
chest indrawing using WHO IMCI definition or pneumo-
nia need for hospital admission based on physician’s assess-
ment); severe pneumonia at community level (based on 
assessment by a trained health worker at home/first level 
facility using WHO IMCI (2005) case definition); and non–
severe pneumonia at outpatient level (defined as fast 
breathing for age in children aged 2 to 59 months). The 
costing model included direct medical cost, direct non–
medical cost and indirect costs. We calculated the cost per 
episode based on the estimates of the unit cost per contact 
(eg, unit cost of an antibiotic per day) at each management 
level multiplied by the resource utilization proportions (eg, 
80% of children took amoxicillin for 5 days), plus indirect 
costs. For the mean total cost of treatment per episode we 
summed the cost of drugs, diagnostic investigations and 
hospital stay, as well as transportation and opportunity cost 
for caregivers’ time. The formula is given in Figure 1.
We reported all cost data in 2013 US$ equivalent prices. 
We first converted all costs to US$ and then adjusted for 
inflation to 2013 values. Conversions were made using the 
Penn World Tables 8.0 (http://www.ggdc.net/pwt) and an 
online inflation–calculating tool (http://usinflation.org/cpi–
inflation–calculator) on 20th October 2013.
Statistical analysis
We have stratified the cost results by country income cate-
gory: high–income countries (HIC) and low– and middle–
income countries (LMIC). As an important input in the cost-
ing analysis for in–patient management, length of stay (LOS) 
in hospital was extracted for severe hospitalized cases. Cost 
per episode, cost by component (direct medical, direct non–
medical and indirect costs), and percentage of total cost per 
episode in each component were summarized. Cost per ep-
isode was synthesized by severity of diseases in each strata. 
The mean with 95% CI of the treatment costs and the me-
dian with interquartile range (IQR) of LOS were estimated 
and reported where appropriate. The 95% CIs were calcu-
lated based on 5000 bootstrap samples. Mean and median 
values were compared using appropriate statistical tests.
Direct medical cost in studies reported from household 
perspective were compared with monthly household in-
come in respective countries to evaluate the burden on 
Figure 1. Formula for the mean total cost of treatment per episode.
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families. Monthly household incomes were derived from 
Gallup World Poll using annual median household income 
divided by 12 months [11]. These income results were 
based on Gallup data gathered between 2006 and 2012 in 
131 populations. In two countries which annual household 
income data was missing, we used GNI per capita from 
World Bank database times the mean number of people per 
household instead. The percentages of direct non–medical 
costs and indirect cost per episode of weekly household 
income were also assessed to show the economic impact of 
pneumonia management for families when direct medical 
cost was not considered.
We conducted all data analyses using SPSS v.19 (IBM, New 
York City, NY, USA) noting that included studies showed 
marked heterogeneity of population, methodology, treat-
ment procedure reporting categories and perspectives.
RESULTS
Search results
We identified 789 studies through database searching, of 
which 60 articles were eligible for full text review on the ba-
sis of title and abstract assessment (Figure 2). Subsequently, 
only 24 papers were identified to be eligible for data extrac-
tion and analysis. The key reasons for exclusions included: 
no data for children below 5 years or no cost data on pneu-
monia management were reported. For unpublished studies, 
we contacted 16 sites, 10 of which had data that met our 
eligibility criteria and contributed to the analysis. The un-
published cost data were for the period January 2001 to Au-
gust 2012. Six of these sites provided cost data using a tem-
plate and guidelines designed for this project while the 
remainder provided unpublished data in their own formats.
Characteristics of published and 
unpublished data
We identified 24 studies from the literature review and col-
lected additional 10 data sets of unpublished studies total-
ling 34 studies from 21 countries across the 6 WHO re-
gions (Table 1). Over 60% of the studies (21 out of 34) 
were conducted in the South East Asia and Africa Regions. 
The included studies reported data from a variety of treat-
ment settings: community, out–patient and in–patient care 
settings in primary, secondary and tertiary hospitals, and 
at city, district, provincial and national levels. Twenty–sev-
en of the 34 studies were stand–alone primary cost analy-
sis and/or cost–of–illness studies. The remaining 7 studies 
were designed to collect cost data alongside clinical trials 
or epidemiological studies.
 
 
 
 
 
Records identified through database 
searching after duplicates removed  
(n = 789) 
Records titles and 
abstracts screened  
(n = 789) 
Records excluded with 
reasons  
(n = 729) 
Full-text articles assessed 
for eligibility  
(n = 60) 
Full-text articles excluded, 
due to no pneumonia specific 
cost data or no data for children 
under 5 years old  
(n = 36) 
 
Studies included in 
quantitative synthesis  
(n = 24) 
Figure 2. PRISMA flow diagram for severe pneumonia cost systematic review.
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Table 1. Characteristics of all studies included*
WHO 
regiOn
COuntry, publiCatiOn year Study pOpulatiOn HealtHCare 
Setting
Severity 
Of 
pneumOnia 
Studied
Study deSign SOurCe Of CaSe 
definitiOn
perSpeCtive Sample 
Size
mean (Sd) /
median age 
Of patientS 
(mOntHS)
data 
SOurCe
High–income countries (number of studies = 8)
EUR Northern Ireland, 
1999 [39]1
Antrim 
(urban)
H2 S QES PD N/A– 45 39.60 
(16.8)
H
Spain, 2013 [17] Barcelona 
(urban)
H3 S, VS Cost analysis‡ Culture–proved 
pneumonia
Healthcare 101 39.60 H
Germany, 2005 [16] National O,H1 S, VS Cost–of–illness PD Societal 402 N/A N, IQ
AMR Chile, Uruguay, 
2007 [12]
National O,H1 S, NS Cost analysis‡ PD, ICD–10 Healthcare 366 N/A H,IQ
United States, 
2012*
Denver, 
Colorado 
(urban)
H3 S, VS, 
NS
Cost–of–illness PD by WHO 
IMCI definition
Societal 940 0–59 H, P
WPR Australia, 2008 [15] National O, H1–3 S Cost analysis‡ ICD–10 Healthcare 1348 N/A N
Australia, 2008 [14] Melbourne, 
Victoria 
(urban)
O,H1 S Cohort study/
cost–of–illness
Health 
professional’s 
diagnosis
Societal 528 N/A N,H,IQ, 
Pilot
Australia, 2011* Sydney 
(urban)
H3 S, VS Cost–of–illness PD by WHO 
IMCI definition
Societal N/A N/A P, 
Market 
price
Low– and middle–income countries (number of studies = 27)
SEAR Bangladesh, 2010 
[26]
Dhaka (urban) H3 S Cost–of–illness PD Family 90 5.00 IQ
Bangladesh, 2005† Dhaka (urban) H3 S, VS Cost–of–illness PD by WHO 
IMCI definition
Household 114 70.32 IQ
Bangladesh, 2010 
[24]
Mirpur, Dhaka 
(urban)
O, H2 S RCT/CEA PD by WHO 
IMCI definition
Societal 360 8.00 –
Bangladesh, 2010† Barishal, 
Bogra, 
Comilla, 
Kishoregonj 
(urban)
H3 S, NS Cost–of–illness PD by WHO 
IMCI definition
Societal 235 N/A IQ
Bangladesh, 2012† Mohakhali, 
Dhaka (urban)
H3 S, VS, 
NS
Cost–of–illness PD by WHO 
IMCI definition
Societal 340 N/A H
India, 2009 [30] Vellore (rural) H1, H2 S Cost–of–illness PD by WHO 
IMCI definition
Healthcare/ 
Household
56 8.8 H, IQ
India, 2002 [29] Berhampur, 
Orissa (urban 
and rural)
H3 S Epidemiologi-
cal study
PD Societal 52 N/A H, IQ
Indonesia, 2001† Lombok 
(rural)
H3 S Cost–of–illness PD by WHO 
IMCI definition
Societal N/A N/A H
Pakistan, 2003 [25] Peshawar city 
(urban)
H3 S RCT/CEA PD by WHO 
IMCI definition
– 126 N/A –
Pakistan, 2006 [20] Ghizer district 
(rural)
O, H1, 
H2
S, NS Cost analysis‡ PD Societal 502 N/A IQ
Pakistan, 2008 [19] Ghizer district 
(rural)
O, H1, 
H2
S, VS, 
NS
Cost analysis‡ PD by WHO 
IMCI definition
Healthcare 141 N/A IQ
Pakistan, 2010† Matiari (rural) C S Cost–of–illness PD by WHO 
IMCI definition
Healthcare N/A N/A Surveil-
lance
Pakistan, 2012 [23] Haripur 
district (rural)
C, H1, H2 S Cost analysis‡ WHO 
definition by 
health worker
Household 423 N/A H, IQ
Viet Nam, 2010 [18] Nha Trang city 
(urban)
H2 S, VS, 
NS
Cost–of–illness PD by WHO 
IMCI definition
Healthcare 788 12.67 N, H
Viet Nam, 2001 [28] Ba Vi district 
(rural)
C, O, H1 S Cost analysis‡ WHO 
definition, 
self–reported
Household 94 N/A IQ
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The included studies reported cost data on a total of 97 062 
children treated at facility or community levels, with a me-
dian sample size of 378 (IQR 117–741) across all studies. 
The age of the participants was reported in 12 studies and 
the median age was 12.3 months (IQR 8.20–33.20). The 
perspective of costing was explicitly stated in 30 of 34 stud-
ies. Of these, the most common perspectives were societal 
(16 out of 33, 1 study did not specify perspective), health 
care (11 out of 33) and household (5 out of 33). In most 
studies, the sources of pneumonia case definition were 
physician’s diagnosis according to WHO IMCI definition 
(29 out of 34), culture–proved pneumonia was used for 
case definition in 1 study, self–reported condition accord-
ing to WHO IMCI definition was adopted in one study, and 
two studies used health workers’ diagnosis. A number of 
different sources were used for gathering cost data, the 
most common being through hospital records and costing 
interviews/questionnaires. Interviews and questionnaires 
were commonly used in studies with a household perspec-
tive to collect data on indirect costs. Other sources includ-
ed a national database of costs, insurance databases, sur-
veillance data and pharmaceutical databases. The WHO 
CHOICE database, expert opinion and data from pilot 
studies were also used to collect data on the unit cost of 
pneumonia treatment.
The average quality score of 24 published studies was 8.21 
out of 13 on scale based on modified Drummond checklist 
(range 3–12) (Appendix S5 in Online Supplementary 
Document). The majority of the studies failed to consider 
discounting and did not perform sensitivity analyses. There 
were 6 studies considered high quality, 14 studies were me-
dium quality, and 4 low quality studies. All studies were 
included into the final analysis.
WHO 
regiOn
COuntry, publiCatiOn year Study pOpulatiOn HealtHCare 
Setting
Severity 
Of 
pneumOnia 
Studied
Study deSign SOurCe Of CaSe 
definitiOn
perSpeCtive Sample 
Size
mean (Sd) /
median age 
Of patientS 
(mOntHS)
data 
SOurCe
AFR Guinea, 1998 [21] National O, H1 S, NS CEA PD – 73650 N/A H, E
South Africa, 2011 
[33]
Pretoria 
(urban)
H3 S, VS Cost analysis‡ WHO 
definition
– 3014 N/A H
South Africa, 2012 
[22]
National H3 S, VS, 
NS
RCT PD Societal/
health care
745 N/A H, IQ
South Africa, 2001† Soweto 
(urban)
H3 S, VS Cost–of–illness PD by WHO 
IMCI definition
Societal 509 14.00 H,IQ
Kenya, 2009 [32] National H3, H2, 
H1
S Cost analysis‡ PD Societal 205 12.00 H, IQ
Zambia, 2009 [31] Kanyama 
Township 
(urban)
O,H2 S Cost analysis‡ PD Healthcare 9146 N/A N,H,P,W
AMR Colombia, 2013 
[27]
National H1,H2,H3 S, VS, 
NS
Cost–of–ill-
ness§
WHO 
definition, 
radiographical-
ly diagnosed
Healthcare 1545 N/A I
Brazil, 2011† Goiânia 
(urban)
H3 S, VS Cost–of–ill-
ness§
PD by WHO 
IMCI definition
Societal 79 0–36 H, N
Argentina, 2012† Buenos Aires 
(urban)
H3 S, VS Cost–of–ill-
ness§
PD by WHO 
IMCI definition
Societal N/A N/A N
Brazil,2007 [12] National O,H1 S, NS Cost analysis‡ PD, ICD–10 Healthcare 366 N/A H,IQ
WPR Fiji, 2012 [34] Viti Levu 
(urban and 
rural)
O S Cost analysis‡ PD by WHO 
IMCI definition
Societal/
household
390 N/A N,H, IQ
EMR Jordan, 2010 [35] Amman H1 S Cohort study PD – 728 4.30 N/A
*Severity of pneumonia: NS – non severe, S – severe, VS – very severe. Data source: H – hospital records, N – national data, IQ – interviews and ques-
tionnaires, I – insurance database, P – pharmacy database, W – WHO database. Treatment settings: H3 – tertiary hospital in–patient, H2–secondary 
hospital in–patient, H1 – primary hospital inpatient, O – out–patient care, C – community ambulatory care; PD – physician’s diagnosis, CEA – cost ef-
fectiveness analysis, RCT – randomized clinical trial, QES– quasi–experimental study, N/A – not available, PD – physician’s diagnosis, IMCI – Integrated 
Management of Childhood Illness, WHO – World Health Organization, SD – standard deviation.
EUR – Europe Region, AMR – the Americas Region, WPR – Western Pacific Region, SEAR – South East Asia, AFR– The Africa Region, EMR– Eastern 
Mediterranean Region
†Unpublished data.
‡The analysis of the comparative costs of alternative treatments or health care programmes.
§The cost analysis of treatment of a disease.
Table 1. Continued
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Cost of management per episode of 
pneumonia
Cost results stratified by income category are presented in 
Table 2, Table 3 and Figure 3. In HICs, the mean cost of 
treatment for an episode of severe pneumonia at the hos-
pital out–patient level was US$ 251.1 in Germany [16]. An 
Australian study [14] reported similar cost of US$ 254.9 
for community management of severe pneumonia. Average 
costs of facility based case management for young children 
admitted in primary/sary and tertiary hospitals were US$ 
2803.5 (95% CI IQR 2000.6–3683.3), and US$ 7037.2 
(95% CI 4028.6–11 311.0) respectively, which was 11–28 
fold higher than in those managed as out–patients. The to-
tal cost per episode for the management of non–severe 
pneumonia at out–patient level was also reported for three 
countries: US$55.8 in Uruguay [12], US$ 272.7 in Chile 
[12] and US$ 334.6 in the United States [36]. The cost for 
very severe pneumonia managed in general pediatric wards 
followed by intensive care unit (ICU) care was reported to 
be US$9151.3 in a tertiary hospital in Spain [17] and US$ 
120 576.3 in the United States, which is nearly 2–17 fold 
of the cost for severe pneumonia management in hospital 
settings in HICs. The majority of studies from HIC took 
only direct medical costs into consideration. Only two 
studies included direct non–medical costs and indirect 
costs [16]. The mean proportion of the total cost for direct 
medical, direct non–medical and indirect costs were 
41.5%, 19.5% and 38.5% respectively.
In LMICs, the cost of case management for severe pneumo-
nia was reported across all treatment settings. The commu-
nity management cost was only reported in studies conduct-
ed in South–East Asia region, with a mean cost of US$ 4.3 
(95% CI 1.5–8.7) per episode. Out–patient care mean costs 
were US$ 51.7 (95% CI 17.4–91.0) per case. Costs for in–
patient care varied by regions, level of hospitals (primary/
sary/tertiary), and levels of care offered at a facility: the mean 
cost for primary/sary hospital care was 242.7 (95% CI 
153.6–341.4) and for tertiary/teaching hospital was 559.4 
(95% CI 268.9–886.3). Two groups–severe pneumonia by 
WHO IMCI definition and hospitalized pneumonia by phy-
sician’s diagnosis–showed similar costs in all levels of care. 
The in–patient care costs were 4–11 fold greater than that 
for out–patient care in the LMICs strata, which in turn was 
significantly higher than that for community management.
Table 2. Cost per episode for childhood pneumonia management in high–income countries
Severity WHO 
regiOn
COuntry, publiCatiOn year perSpeCtive Sample 
Size
COSt per epiSOde (2013 uS$) COSt COmpOnent, % Of tOtal 
COSt per epiSOde
Tertiary/teaching 
hospital in–patient 
care
Secondary/
primary 
hospital 
in–patient care
Out–
patient 
care
Com-
muni-
ty care
Di-
rect 
med-
ical
Direct 
non–
medical
Indi-
rect
Non–severe 
pneumonia
AMR US, 2012* Societal 940 334.6
Chile, 2007 [12] Healthcare 366 272.7
Uruguay, 2007 [12] Healthcare 366 55.8
Non–severe pneumonia mean cost (95% CI) 221.0 (55.8–334.6)
Severe 
pneumonia 
by WHO 
IMCI 
Definition
AMR Chile, 2007 [12] Healthcare 366 4316.7 100
Uruguay, 2007 [12] Healthcare 366 1421.6 100
US, 2012* Societal 940 15 029.2
EUR North Ireland, 1999 
[13]
NA 45 5733.8, 2716.8 100
WPR Australia, 2011* Societal NA 6,259.1 93.1 6.9
Hospitalised 
pneumonia
WPR Australia, 2008 [14] Societal 528 2813.1 254.9 100
Australia, 2008 [15] Healthcare 1348 2307.8 100
EUR Germany, 2005 [16] Societal 402 3158.6 251.1 41.5 19.5 38.5
Spain, 2013 [17] Healthcare 101 5447.3 100
Severe pneumonia mean cost (95% CI) 7037.2  
(40 286–11 311.0)
2803.5  
(2000.6–3683.3)
251.1 254.9
Very severe 
pneumonia 
by IMCI
AMR US, 2012* Societal 940 120 576.2
Very severe 
pneumonia 
requiring 
critical care
AMR Spain, 2013 [17] Healthcare 101 9151.3
Very severe pneumonia mean cost (95% CI) 64 863.8 (9151.3–120 576.3)
NA – Information not available, EUR – Europe Region, AMR – The Americas Region, WPR – Western Pacific Region, CI – confidence interval, IMCI – 
Integrated Management of Childhood Illness
*Unpublished data.
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Table 3. Cost per episode for childhood pneumonia management in low– and middle–income countries
Severity WHO 
regiOn
COuntry, publiCatiOn year perSpeCtive Sample 
Size
COSt per epiSOde (2013 uS$) COSt COmpOnent, % Of 
tOtal COSt per epiSOde
Tertiary/teaching 
hospital 
in–patient care
Secondary/
primary 
hospital 
in–patient care
Out–patient 
care
Commu-
nity care
Direct 
medi-
cal
Direct 
non–
medi-
cal
In-
di-
rect
Non–severe 
pneumonia
SEAR Viet Nam, 2010 [18] Healthcare 788 28.6
Pakistan, 2008 [19] Healthcare 141 29.4
Pakistan, 2006 [20] Societal 502 94.1–17.8
Bangladesh, 2012* Societal 340 5.7
AFR Guinea, 1998 [21] NA 73 650 3.2
South Africa, 2012 [22] Societal/
health care
745 263.1
AMR Brazil, 2007 [12] Healthcare 366 93.0
Non–severe pneumonia mean cost (95% CI) 66.9 (21.7–129.7)
Severe 
pneumonia 
by WHO 
IMCI 
Definition
SEAR Pakistan, 2010* Healthcare NA 8.7 100
Pakistan, 2012 [23] Household 423 7.9 1.5 89.1 1.3 9.6
Bangladesh, 2012* Societal 340 5.7
Bangladesh, 2010 [24] Societal 360 193.6 124.0 Y Y
Viet Nam, 2010 [18] Healthcare 788 39.5 Y Y Y
Pakistan, 2008 [19] Healthcare 141 186.0 64.1 35.9
Pakistan, 2003 [25] NA 126 20.3 100
Bangladesh, 2005* Household 114 80.6† 62.6# 70.9† 29.1†
Bangladesh, 2010 [26] Household 90 124.2 67.6 32.4
Indonesia, 2001* Societal NA 135.2 75 25
AFR Guinea, 1998 [21] NA 73650 110.6 69 30
South Africa, 2001* Societal 509 480.9§ 110.0
AMR Brazil, 2007 [12] Healthcare 366 461.0 100
Brazil, 2011* Societal 79 1474.1†,‡ 594.5# 94† 1† 5†
Colombia, 2013[27] Healthcare 1545 517.6 100
Argentina, 2012* Societal NA 1648.0 100
Hospitalised 
pneumonia
SEAR Viet Nam, 2001 [28] Household 94 2.7 56–88 Y
Pakistan, 2006 [20] Societal 502 310.8 127.6 45.3 55
India, 2009 [29] Healthcare/
household
56 145.7 44.7 45.7 5.3 47.4
India, 2002 [30] Societal 52 23.9 100
AFR Zambia, 2009 [31] Healthcare 9146 249.7 55.7 100
Kenya, 2009 [32] Societal 205 236.8 162.1, 89.5 86 14 Y
South Africa, 2011 [33] Societal 509 491.4†, 1553.2‡ 100
South Africa, 2012 [22] Societal/
health care
745 1223.1 98 2 0.2
WPR Fiji, 2012 [34] Societal/
household
390 25.7, 15.6 61.9 33.2 4.9
AMR Colombia, 2013 [27] Healthcare 1545 304.4 76.2
EMR Jordan, 2012* NA 728 563.4 100
Severe pneumonia mean cost (95% CI) 559.4  
(268.9–886.3)
242.7 
(153.6–341.4)
51.7 
(17.4–91.0)
4.3  
(1.5–8.7)
Very severe 
pneumonia 
by IMCI
SEAR Bangladesh, 2012* Societal 340 15.7
Viet Nam, 2010 [18] Healthcare 788 61.2
Pakistan, 2008 [19] Healthcare 141 81.3
Very severe 
pneumonia 
requiring 
critical care
AFR South Africa, 2011 [33] NA 3014 849.0†
14795.4‡
South Africa, 2012 [22] Societal/
health care
745 6696.2
AMR Colombia [27] Healthcare 1545 3643.4
Very severe pneumonia mean cost (95% CI) 6496.0 
(2246.2–12 007.4)
71.3 
(61.2–81.3)
15.7 
(15.7–15.7)
NA – information not available, Y – authors considered the cost component, but the proportion was unknown, EUR – Europe Region, AMR – The Amer-
icas Region, WPR – Western Pacific Region, SEAR – South East Asia, AFR – The Africa Region, EMR – Eastern Mediterranean Region
*Unpublished data.
†Public health care.
‡Private health care.
§Pediatric ward.
#Supplementary health system.
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The costs for management of non–severe pneumonia man-
aged at outpatient level were US$ 66.9 (95% CI 21.7–
129.7), which was slightly higher than for severe cases at 
outpatient level. This is because the hospital short stay for 
non–severe pneumonia in South Africa [22] was relatively 
high at US$ 263.1 per episode. The mean cost for very se-
vere cases was US$ 6496.0 (2246.2–12 007.4), which is 
nearly 10-fold of severe case management cost.
There were 6 studies reporting cost from household per-
spective, mainly from LMICs in South East Asia Region. 
Direct medical cost for severe pneumonia in hospital inpa-
tient settings were 26.6%–115.8% of the monthly house-
hold income, thus demonstrating that severe pneumonia 
management in hospital placed a significant financial bur-
den on families. On the other hand, outpatient and com-
munity management of severe pneumonia accounted for 
only 0.4%–4.1% of family’s monthly income indicating de-
creased burden in these settings. (Table 4).
Of the papers reporting cost component of severe pneumo-
nia management, direct medical cost was reported across all 
studies and accounted for 45%–100% of the total cost. The 
mean direct non–medical cost and indirect cost were US$ 
22.0 (11.8–32.7) and US$ 27.0 (4.0–54.3) respectively, 
which account for 0.5%–31.0% of weekly household in-
come (Table 5).
Length of stay in hospital
The in–patient cost was determined primarily by the length 
of stay (LOS) and the average cost per bed day. In this re-
view, we extracted length of stay for severe pneumonia for 
future costing analysis reference (Tables 6–8).
Table 4. Direct medical cost for severe pneumonia management in low– and middle–income countries reported from household 
perspective
COuntry, publiCatiOn year direCt mediCal COSt (2013 $uS; % Of direCt mediCal COSt tO mOntHly HOuSeHOld inCOme) mOntHly HOuSeHOld 
inCOme (2013 $uS)*
Tertiary/teaching 
Hospital in–patient care
Secondary/primary 
hospital in–patient care
Out–patient care Community 
ambulatory care
Bangladesh, 2010 [26] 124.2 (52.9%) – – – 234.9
Bangladesh, 2005† 80.6‡ (34.3%) 62.6§ (26.6%) – 234.9
India, 2009 [30] 305.8 (115.8%) 135.1 (64.7%) – – 264.0
Pakistan, 2012 [23] – – 7.9 (2.3%) 1.5 (0.4%) 338.3
Viet Nam, 2001 [28] – – – 2.7 (0.7%) 398.6
Fiji, 2012 [34] – – 25.7 (4.1%)/15.6 (2.5%) – 632.5‡
*Monthly household income (2913 US$) were derived from Gallup World Poll annual median household income, equals annual median household 
income divided by 12. These results were based on Gallup data gathered between 2006 and 2012 in 131 population. Source: http://www.gallup.com/
poll/166211/worldwide-median-household-income-000.aspx.
†Numbers used GNI per capita based on purchasing power parity (PPP) due to lack of monthly household income data. Source: http://data.worldbank.
org/indicator/NY.GNP.PCAP.PP.CD/countries.
‡Public health care.
§Supplementary health system.
Figure 3. Range of cost per episode for 
pneumonia management (2013 US$).
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Table 6. Length of stay of very severe pneumonia and severe 
pneumonia in hospital in high–income countries
COuntry and year Setting lOS (Sd) dayS Sample 
Size
Very severe pneumonia:
Germany, 2005 [16] ICU 7.4 (6.1) 2039
Spain, 2013 [17] ICU 18.0 99
USA, 2012* ICU 18.3 (43.1) 1116
Australia, 2011* ICU 11.0 –
Median (IQR) 14.5 (10.1–18.1)
Severe pneumonia:
Ireland, 1999 [13] Control group 8.3 (7.7–9.0) 44
New treatment group 4.0 (3.5–4.6) 45
Germany, 2005 [16] Hospitalised cases 7.4 (6.1) 2039
Australia, 2008 [14] Without impact diary 8.8 202
With impact diary 13.5 523
Australia, 2011* Non–ICU 6.0 –
Spain, 2013 [17] Non–ICU 10.5 99
USA, 2012* Non–ICU 2.7 (2.3) 940
Median (IQR) 7.9 (5.5–9.2)
IQR – interquartile range, ICU – intensive care unit
*Unpublished data.
Table 5. Direct non–medical cost and indirect cost per episode for severe pneumonia management in low– and middle–income 
countries
COuntry, publiCatiOn year direCt nOn–mediCal COSt* indireCt COSt† % Of nOn–mediCal COSt tO 
mOntHly HOuSeHOld inCOme
mOntHly HOuSeHOld 
inCOme (2013 uS$)Total Transportation Food Total
Bangladesh, 2010 [24] 32.4 13.8% 234.9
India, 2002 [29] 5.3 5.3 47.5 2.0% 264.0
Pakistan, 2008 [19] 35.9 12.2 23.7 10.6% 338.3
Pakistan, 2006 [20] 55.0 16.3% 338.3
Pakistan, 2012 [23] 3.3 2.3 1.0 9.6 1.0% 338.3
Kenya, 2009 [32] 14.0 9.0% 155.8
Guinea, 1998 [21] 30.0 31.0% 96.7‡
South Africa, 2012 [22] 2.0 1.4 0.2 0.5% 434.8
Fiji, 2012 [34] 33.2 33.2 4.9 5.3% 632.5‡
Brazil, 2011* 9.7 8.41 1.31 73.1 1.6% 626.8
Mean (95% CI) 22.0 (11.8–32.7) 10.5 (3.5–22.3) 8.7 (1.0–23.7) 27.0 (4.0–54.3)
Median (IQR) 22.0 (4.6 –33.9) 6.9 (2.1–11.5) 1.3 (–) 9.6 (2.5–60.3)
CI – confidence interval, IQR – interquartile range
*Direct medical costs include medications and consultation, non–medical cost includes transportation, food and accommodation.
†Indirect cost refers to parental loss of earnings in the period of illness. Monthly household income (2013 US$) was derived from Gallup World Poll 
annual median household income, equals annual median household income divided by 12. These results were based on Gallup data gathered between 
2006 and 2012 in 131 populations. Source: http://www.gallup.com/poll/166211/worldwide-median-household-income-000.aspx.
‡Numbers used GNI per capita based on purchasing power parity (PPP) due to lack of monthly household income data. PPP GNI is gross national in-
come (GNI) converted to international dollars using purchasing power parity rates. An international dollar has the same purchasing power over GNI as 
a US dollar has in the United States. GNI is the sum of value added by all resident producers plus any product taxes (less subsidies) not included in the 
valuation of output plus net receipts of primary income (compensation of employees and property income) from abroad. Source: http://data.worldbank.
org/indicator/NY.GNP.PCAP.PP.CD/countries.
The mean LOS for severe pneumonia reported in individ-
ual studies ranged from 4–13.5 days, with a mean LOS 7.7 
(95% CI 5.5–9.9) days and median 7.9 (IQR 5.5–9.2) days 
in HIC, and mean LOS 5.8 (95% CI IQR 5.3–6.4) days and 
median 6.4 (IQR 4.1–7.1) days in LMIC. For very severe 
pneumonia management in intensive care unit (ICU), LOS 
ranged from 7.4 to 18.3 days. The mean and median LOS 
were 13.7 (95% CI IQR 9.2–18.2) and 14.5 (IQR 10.1–
18.1) days in HIC, and 9.5 (95%CI, 7.4–11.8) and 9.2 
(IQR 6.1–12.6) days in LMIC.
Unit cost of case management
Unit cost of treatment and resource uptake should be rou-
tinely reported in cost studies. However, only 13 of the 34 
included studies reported these data. Since treatment pro-
tocols (use of antibiotics, diagnostic tests, procedures and 
levels and intensity of care) varied between studies, this 
contributed to variations in costs across studies. For exam-
ple, the average cost of chest radiograph in LMIC was US$ 
8.4 (95% CI 4.3–27.0), which was significantly lower than 
US$ 185.5 (95% CI 66.3–357.7) in high income countries 
(Table 9). We attempted to abstract unit cost data but were 
unable to include it in the presented direct medical costs 
because of paucity of information.
DISCUSSION
This is the first attempt to conduct a systematic review of 
all published and available unpublished cost data on the 
management of childhood pneumonia. Costs per episodes 
in HICs were 5–13–fold higher in all delivery channels 
than those in LMICs. The review demonstrates that the 
magnitude of cost per episode increases markedly as the 
level of treatment delivery rises. Community management 
for severe pneumonia was less than 10% that of the cost of 
out–patient management among all levels of management 
in LMICs. Thus, there are strong economic reasons for con-
sidering community case management as a central strategy 
for pneumonia case management in low income countries; 
this merits further evaluation which should include con-
sideration of medical outcomes. The mean lengths of stay 
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Table 7. Length of stay of severe pneumonia in hospital in low– and middle–income countries
COuntry, year deSCriptiOn lengtH Of Stay (Sd) in dayS‡ Sample Size
Viet Nam, 2010 [18] Probable pneumonia 7.2 (5.0) 40
Radiograph confirmed 6.7 (3.8) 426
Probable severe pneumonia 6.2 (3.3) 59
Radiograph confirmed severe pneumonia 6.4 (2.7) 193
Bangladesh, 2010 [24] Hospital care 6.0 (5.0–7.0) 180
Bangladesh, 2005* Public health care 7.1 73
Private health care 6.4 41
Bangladesh, 2010* Hospital stay 7.0 (3.0)† 93
Pakistan, 2003 [25] Antibiotic use duration Approx. 8 124
Kenya, 2009 [32] National hospitals 8.2 49
District hospitals 6.7 30
District hospitals 4.8 29
District hospitals 4.2 17
Provincial hospitals 6.6 31
Mission Hospitals 7.8 30
Mission Hospitals 3.4 19
Zambia, 2009 [31] Tertiary health center 4.0 221
Pakistan, 2008 [19] Time spent at health facility for severe pneumonia 3.3 65
Pakistan, 2006 [20] Secondary hospital 3.0 502
Jordan, 2010 [35] In–patient days 4.0–5.0 728
India, 2009 [30] Secondary hospital 3.5 (2.9–4.1) 31
Tertiary hospital 3.7 (3.0–4.4) 25
India, 2002 [29] Tertiary hospital 6.5 (2.5) 52
Brazil, 2011* Public health system 3.9 (2.2) 59
Supplementary health system 5.3 (4.7) 20
Colombia, 2013 [27] Primary 2.0 (1.0–2.0) 247
Secondary hospital 4.0 (1.0–5.0) 1208
Tertiary hospital 6.0 (3.0–9.0) 47
South Africa, 2011 [33] Public sector ward 8.7 86
Fee for service sector 5.6 7786
South Africa, 2012 [22] Paediatric ward 8.1 (7.4–8.8) 513
Indonesia, 2001* Non–ICU 6.7 –
Argentina, 2012* Severe pneumonia 7.5(8.5) 42
Unilateral focal pneumonia without complications 7.4 (6.0) 1994
Multifocal pneumonia without complications 8.0 (6.5) 323
Median (IQR) 6.4 (4.1–7.1)
ICU – intensive care unit
*Unpublished data.
†Combined HIV+ and HIV–, HIV+ had longer stay in ward (9.3 vs 7.0 days).
‡Length of stay (LOS) reported as mean, mean (standard deviation) or median (interquartile range). When stratified LOS available, then stratified LOS 
was reported, not average length of stay of all pneumonia.
in hospital for severe pneumonia were 1.8–4.6 days less in 
LMIC compared to HIC, and at a mean of 5.8 and median 
of 6.4 days, were close to the WHO recommendation of 5 
days in–patient treatment [10].
We demonstrated that the cost (per episode) for the man-
agement of severe pneumonia varied greatly by unit cost of 
intervention, disease severity and treatment procedures in 
different settings. The review also demonstrated that major 
factors governing the total cost per episode were length of 
stay in the hospital, countries income level and the pres-
ence or absence of community case management for pneu-
monia. Many other studies have also found GDP per cap-
ita to be the main driver of costs [37]. These findings 
demonstrate that choosing the appropriate value for these 
inputs will have a significant influence on the total cost. 
Existing studies calculated pneumonia management costs 
in many countries assuming the same treatment procedure 
and unit cost of medicine. However, the cost data we col-
lected demonstrate that this method may have limitations; 
the uncertainty in the traditional estimates can be measured 
using the cost data reported in this review.
Our results showed that direct medical costs for childhood 
pneumonia management, especially inpatients, represent a 
significant proportion of the average monthly household 
income for families in LMICs. This is often compounded 
by further direct non–medical cost and indirect cost ie, loss 
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the funds: many borrow or take high–interest loans [26]. 
Furthermore, Ayieko et al found that 10% of the patients in 
district hospitals and up to 25% of children in tertiary hos-
pitals wait in hospital beds after medical discharge while 
families source the fees. The latter translates to an addition-
al cost of US$ 17.46 to the public provider and US$ 5.32 
to the family [32], resulting in a drain on both the resourc-
es of the family and the health care provider, as well as de-
nying a bed to another sick child. It is therefore important 
that national strategies for pneumonia management in 
LMIC are not only cost–effective for the national program 
but also give attention to the burden of costs on families so 
that these are maintained at a level that is affordable.
The data in this review comprise “actual” cost data measured 
in cost studies conducted in many LMIC and HIC. We be-
lieve that these represent a fair first approximation of true 
costs in these countries. It is noteworthy that the resulting 
cost estimates are higher than those currently contained in 
the WHO–CHOICE estimates [38]. Three factors could have 
contributed to this variation. First, we identified longer facil-
ity and hospital stays compared to standard treatment pro-
tocols recommended by the WHO [39]. Moreover, most ex-
isting cost studies were conducted at tertiary level hospitals 
where out–patient and in–patient treatments carry a much 
higher cost compared to the community or first level facility. 
Third, the wide variety of antibiotics (including variations in 
dosage, route of administration and duration) across the 
sites, as well as the heterogeneity in the costing methodol-
ogy and the cost components in existing studies may have 
led to higher estimates.
Table 8. Length of stay of very severe and non–severe pneumonia in hospital in low– and middle–income countries
COuntry, year deSCriptiOn lengtH Of Stay (Sd) dayS Sample Size
Very severe pneumonia
Viet Nam, 2010 [18] Very severe pneumonia 6.4(2.7) 26
Confirmed very severe pneumonia 5.8 (3.0) 44
Colombia, 2013 [27] ICU 13.0 (6.0–14.0) 43
South Africa, 2011 [33] ICU 9.4 46
ICU 10.5 93
South Africa, 2012 [22] ICU 14.4(10.3–18.5) 7
Pakistan, 2008 [19] Time spent at health facility for very severe pneumonia 3.9 35
Argentina, 2012† Very severe pneumonia 8.9 –
Unilateral focal pneumonia without complications 17.2 –
Multifocal pneumonia without complications 11.5 –
Brazil, 2011* Public health system 6.9 –
Supplementary health system 6 –
Median (IQR) 9.2 (6.1–12.6)
Non severe pneumonia
Pakistan, 2008 [19] Time spent at health facility for pneumonia 0.3 41
South Africa, 2012 [22] Short stay 1.4 (1.3–1.6) 338
Median (IQR) 0.9 (0.3–1.4)
ICU – intensive care unit, IQR – interquartile range
*Unpublished data.
†Note added in proof: The data from this study are unpublished but the data on the length of stay are published in Giglio ND, Cane AD, Micone P, Gen-
tile A. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine. 2010;28:2302-10. Med-
line:20064478
Table 9. Chest Radiography cost per episode
COuntry, year COSt per epiSOde (uS$, 2013)
High income 
countries
Australia, 2011* 129.8
Chile, 2007 [12] 135.1
Uruguay, 2007 [12] 43.4
United States, 2012* 433.7
Mean(SD) 185.5 (66.3–357.7)
Median(IQR) 132.5 (108.2–209.8)
Low– and 
middle–
income 
countries
Argentina, 2012* 26.7
Brazil, 2011* 10.7
6.0
Brazil, 2007 [12] 13.63
Bangladesh, 2010* 2.3
India, 2009 [30] 5.4
Pakistan, 2008 [19] 3.2
Indonesia, 2001* 4.6
Kenya, 2009 [32] 2.3
South Africa, 2001* 29.7
South Africa, 2011 [33] 59.7
137.2
South Africa, 2012 [22] 27.7
Mean (SD) 25.3 (9.8–47.3)
Median (IQR) 8.4 (4.3–27.0)
*Unpublished data.
of earnings when caring for the sick child. In countries 
where these families were uninsured, health payments for 
pneumonia management were a heavy burden on house-
hold and can have a significant impact on the family, par-
ticularly when the payments for care were out–of–pocket 
in most LMIC countries. Alamgir et al investigated the im-
pact that this strain had on families and how they source 
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This review has several limitations. First, the primary goal 
of the systematic review was to obtain data on cost of man-
agement (per episode) of severe pneumonia. However, the 
lack of any standard management protocols (which varied 
widely across the included studies) and the general lack of 
service uptake data, may have contributed to the substantial 
uncertainty around the estimates. Second, we did not in-
clude costs of diagnostic investigations in the cost modeling 
in some study sites, because country–specific unit prices and 
utilization data were not available. Therefore, the true eco-
nomic burden resulting from the management of childhood 
pneumonia could be considerably higher. Third, costs were 
highly dependent on level of care offered at facility and LOS 
could be skewed to longer period if high level of care (such 
as intensive care unit (ICU) care) was offered to severe and 
very severe cases. In this review, severe cases were all man-
aged at non–ICU hospital settings, and very severe cases 
were managed at both non–ICU and ICU care in hospital 
settings. We were able to report LOS separately for non–ICU 
and ICU care but this stratification was not possible for total 
cost per episode. A further limitation was that the definition 
of ICU and ICU care may vary by country. Fourthly, we lim-
ited the search to English articles only, which may exclude 
some cost reported in other languages, however only 13 
studies out of 789 articles in other languages were found. 
We tried to compliment this with unpublished data from 
non–English speaking countries. Lastly, there was a wide 
range in per capita income and health care system and pay-
ment schemes within LMIC category and the existing cost 
data may only reflect the situation when and where the data 
were collected and may not be representative of the whole 
country or the current situation. Furthermore, there were 
not sufficient studies to address all possible cost scenarios to 
facilitate international and public/private comparisons.
Our results demonstrate that further research on the eco-
nomic burden due to the management of childhood pneu-
monia is needed, with clear reporting of data on unit cost 
of intervention, dosage of various drugs and information 
on health care utilization, such as length of stay in hospital. 
We recommend that standard reporting of unit cost of in-
tervention with direct medical and non–medical costs and 
indirect costs, standard treatment protocols and health re-
source utilization in conjunction with the total cost per 
episode in any cost–of–illness studies would facilitate eco-
nomic estimates of national scale–up and international 
comparisons. Further studies on the cost–effectiveness of 
standardized IMCI protocol against other treatment proto-
cols could be expected to find a cost–saving management 
strategy for high burden countries.
Identifying the most cost–effective interventions for pneu-
monia management is essential for achieving the goal of 
further reducing child mortality. Our study demonstrated 
that early treatment in the community costs less (per event) 
than late treatment in the hospital. This finding suggests 
that the public health community should explore ways for 
community outreach for early diagnosis and treatment be-
fore severe pneumonia sets in. The results from this sys-
tematic review provide important missing information on 
the cost of pneumonia treatment in children across many 
countries. These data and the cost estimates should provide 
important information useful to program managers and 
policy makers at national and regional levels, international 
agencies, and donor organisations to aid resource alloca-
tion, program planning and priority setting. The estimates 
presented in this review could enable a more detailed eco-
nomic evaluation of the revised WHO pneumonia manage-
ment guidelines [39], and help identify the most cost–ef-
fective preventive and treatment interventions for reducing 
the burden of childhood pneumonia.
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